Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Mental exercises may help reverse age-related cognitive decline

Mental exercises may help reverse age-related cognitive decline

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories reports first-quarter diluted EPS of $0.39

Researchers use bioelectric signals of brain to detect neurodegenerative diseases

Researchers use bioelectric signals of brain to detect neurodegenerative diseases

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Olig1 and Olig2 genes are associated with Down syndrome, scientists identify

Olig1 and Olig2 genes are associated with Down syndrome, scientists identify

Lab-on-Bead technology helps researchers cut years from drug development

Lab-on-Bead technology helps researchers cut years from drug development

All dementia isn't Alzheimer's disease: Mayo Clinic

All dementia isn't Alzheimer's disease: Mayo Clinic

Johns Hopkins Hospital takes top spot in annual rankings of American hospitals for 20th year in a row

Johns Hopkins Hospital takes top spot in annual rankings of American hospitals for 20th year in a row

Penn researchers reverse cognitive decline in fruit flies with Alzheimer's gene mutation

Penn researchers reverse cognitive decline in fruit flies with Alzheimer's gene mutation

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

Researchers use new biomarkers to study structure of protein deposits caused by Alzheimer's disease

Researchers use new biomarkers to study structure of protein deposits caused by Alzheimer's disease

Plexxikon announces promising preclinical data of PLX3397

Plexxikon announces promising preclinical data of PLX3397

Dementia varies among diabetic, non-diabetic patients: Research

Dementia varies among diabetic, non-diabetic patients: Research

Scientists awarded $2.3M grant to develop new treatments for drug addiction

Scientists awarded $2.3M grant to develop new treatments for drug addiction

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

MD Buyline identifies top emerging technologies with highest impact

MD Buyline identifies top emerging technologies with highest impact

New research focuses on calcium channels in lysosome membrane

New research focuses on calcium channels in lysosome membrane

Study links obesity to poorer memory, brain function in older women

Study links obesity to poorer memory, brain function in older women

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.